Dispatch Biotherapeutics

Market position

Dispatch positions itself against the broader field of solid-tumor immunotherapy, where CAR-T successes in blood cancers have not translated. Coverage notes that other approaches search for a pre-existing tumor-specific target, an approach that has produced safety failures — for example Tmunity Therapeutics, another Philadelphia company involving Carl June, halted a Phase 1 prostate cancer trial after two patients died of neurotoxicity because the target was also present in healthy tissue. Dispatch instead installs its own target. It is described as part of the next generation of Philadelphia's "Cellicon Valley" biotech cluster, which has recently seen layoffs, closures and a pullback in capital.

Rather than seeking a naturally occurring tumor-specific antigen, Dispatch uses a viral vector to install a synthetic universal antigen onto tumor cells, which the company says is not expressed anywhere else in the patient's body, and simultaneously conditions the tumor microenvironment. This is intended to address both the targeting and the resistance problems in a single product, and to be tumor-type agnostic across epithelial cancers.

Technology

The Flare platform pairs a viral vector with a targeted immunotherapy. The vector delivers a novel universal antigen — Flare — that tags solid tumor cells and simultaneously breaks down the tumor's immunosuppressive microenvironment, and is designed to stimulate the immune system so effector cells can withstand that environment. The Flare antigen then serves as a beacon directing immune cells to find and clear tagged cancer cells while sparing healthy tissue; the company states the target is not present elsewhere in the body. The first-generation immunotherapy component is a CAR-T cell therapy, chosen in part because of existing regulatory precedent for the drug class, though the company says the approach is compatible with other targeted therapies.

Go-to-market

The company plans to move its first program into the clinic in the year following its July 2025 launch, with a Phase 1 trial. It is finalizing IND-enabling studies and establishing manufacturing with an undisclosed partner. Management said it is starting with a homogeneous patient population to prove the strategy and prioritizing indications of highest unmet need where there is no established therapy after first line; the specific first indication was not disclosed, though the CEO cited colorectal and lung cancers as areas of focus. Further scientific detail was to be presented at a scientific conference later in 2025.

Patients with solid tumors, particularly epithelial cancers such as lung and colorectal cancer, in settings of high unmet medical need.

Geography

Dual-site U.S. operations: headquarters at 25 N. 38th St., Suite 600, Philadelphia, PA 19104, and an office at 953 Indiana St., San Francisco, CA 94107. Forty-five of 60 employees are based in Philadelphia.

History

Founded in 2022 in Pennsylvania, Dispatch operated in stealth mode while raising seed and Series A capital totaling $216 million. It launched publicly on July 23, 2025, announcing the Flare platform and its investor syndicate from Philadelphia and San Francisco. At launch the company employed 60 people, with 45 (75 percent) in Philadelphia and the remainder in San Francisco. Board chairman Jeff Marrazzo, who left Spark Therapeutics in 2022, said a condition of his involvement was that the company be based largely in Philadelphia. The company was named to the 2025 Endpoints 11 list, and Marrazzo and Carl June were named Disruptors of the Year by The Philadelphia Citizen, to be honored at an April 22, 2026 awards event.

Risks & controversies

The company is preclinical; press coverage notes it typically takes years to establish whether such products are safe and effective in humans, and that approved therapies of this kind can be extremely expensive. CAR-T approaches in solid tumors have historically encountered on-target/off-tumor toxicity, illustrated by Tmunity Therapeutics halting a Phase 1 prostate cancer trial after two patient deaths from neurotoxicity. The CEO characterized the fundraising environment as the most difficult he had experienced, and the Philadelphia biotech sector has seen layoffs, closures and reduced investment.